Numerous cancer research is taking place around the world at this moment. While some of it has already shown promising results, there remains an undeniably long work ahead before at least one of them can be officially called a cancer cure. However, the so-called “living drug” or technically known as CAR-T therapy is recently igniting hope among cancer patients that cure is on the horizon.
Cancer cure: Patient from London healed
Patients suffering from lymphoma under the United Kingdom’s National Health Services system were previously given access to CAR-T therapy. Now, 62-year-old Mike Simpson swears by the treatment regimen that made his cancer “run.”
BBC also reports that other patients at the King’s College Hospital, London have been ultimately cured of cancer after receiving the same treatment. CAR-T therapy primarily uses immune system cells — T-cells — that have been taken from the cancer patient themselves.
How the potential cancer cure works
The process starts by taking blood samples from the patient and then filtering out the T-cells. It is then modified to specifically recognize cancer cells and combined with a special receptor called a chimeric antigen receptor. Once completed, the CAR-T cells are then injected back to the patient.
The entire process and where the CAR-T cells come from clearly explains why experts have been calling it a living drug. It is essentially a treatment that, instead of being taken in several batches, is being injected to the cancer patients and functions as live cells inside the body.
Cancer cure: It’s effectivity signals expensive cost
According to reports, Simpson was diagnosed with B-cell lymphoma back in 2015 and has had two chemotherapy sessions. They initially neutralized his cancer, but the illness eventually came back and by late 2018 doctors estimated he had about two years left to live. But he received CAR-T therapy last February and following tests show it is effectively working against his cancer cells.
CAR-T therapy is slated to be tested on hundreds of patients in the coming months. Once it is cleared for public consumption, patients who need it, unfortunately, has to face the daunting fact that this possible cancer cure will certainly not come cheap.


Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Tabletop particle accelerator could transform medicine and materials science
Neuralink Expands Brain Implant Trials with 12 Global Patients
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



